TCRX
Price:
$3.02
Market Cap:
$161.18M
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients ...[Read more]
Industry
Biotechnology
IPO Date
2021-07-16
Stock Exchange
NASDAQ
Ticker
TCRX
According to TScan Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.18. This represents a change of -46.12% compared to the average of -5.90 of the last 4 quarters.
The mean historical PE Ratio of TScan Therapeutics, Inc. over the last ten years is -7.42. The current -3.18 PE Ratio has changed 4.18% with respect to the historical average. Over the past ten years (40 quarters), TCRX's PE Ratio was at its highest in in the December 2019 quarter at 0. The PE Ratio was at its lowest in in the March 2020 quarter at -11.35.
Average
-7.42
Median
-4.29
Minimum
-19.98
Maximum
-0.57
Discovering the peaks and valleys of TScan Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 656.78%
Maximum Annual PE Ratio = -0.57
Minimum Annual Increase = -78.01%
Minimum Annual PE Ratio = -19.98
Year | PE Ratio | Change |
---|---|---|
2023 | -4.29 | 656.78% |
2022 | -0.57 | -74.40% |
2021 | -2.21 | -78.01% |
2020 | -10.06 | -49.63% |
The current PE Ratio of TScan Therapeutics, Inc. (TCRX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.36
5-year avg
-7.42
10-year avg
-7.42
TScan Therapeutics, Inc.’s PE Ratio is greater than VectivBio Holding AG (-7.94), greater than Icosavax, Inc. (-15.78), greater than Apellis Pharmaceuticals, Inc. (-16.22), less than iTeos Therapeutics, Inc. (-2.83), greater than Day One Biopharmaceuticals, Inc. (-14.68), less than Acumen Pharmaceuticals, Inc. (-1.52), greater than X4 Pharmaceuticals, Inc. (-7.20), less than Inozyme Pharma, Inc. (-1.95), less than Cognition Therapeutics, Inc. (-0.60), less than TFF Pharmaceuticals, Inc. (-0.02), less than Cue Biopharma, Inc. (-1.20), less than Dermata Therapeutics, Inc. (-0.15), greater than ProQR Therapeutics N.V. (-10.77), greater than Annexon, Inc. (-5.37), greater than Arrowhead Pharmaceuticals, Inc. (-4.37), greater than Terns Pharmaceuticals, Inc. (-5.82),
Company | PE Ratio | Market cap |
---|---|---|
-7.94 | $1.06B | |
-15.78 | $769.04M | |
-16.22 | $4.07B | |
-2.83 | $290.26M | |
-14.68 | $1.29B | |
-1.52 | $124.37M | |
-7.20 | $102.41M | |
-1.95 | $191.44M | |
-0.60 | $21.13M | |
-0.02 | $288.80K | |
-1.20 | $66.20M | |
-0.15 | $2.22M | |
-10.77 | $339.54M | |
-5.37 | $480.74M | |
-4.37 | $2.75B | |
-5.82 | $559.75M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TScan Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TScan Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is TScan Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for TScan Therapeutics, Inc. (TCRX)?
What is the highest PE Ratio for TScan Therapeutics, Inc. (TCRX)?
What is the 3-year average PE Ratio for TScan Therapeutics, Inc. (TCRX)?
What is the 5-year average PE Ratio for TScan Therapeutics, Inc. (TCRX)?
How does the current PE Ratio for TScan Therapeutics, Inc. (TCRX) compare to its historical average?